Genentech Seeks Expanded Use of Avastin in Breast Cancer
Genentech Seeks Expanded Use of Avastin in Breast Cancer
SAN FRANCISCO, CalifGenentech has submitted an application to the FDA for expanded use of bevacizumab (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.
Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Related Videos
Related Content
